openPR Logo
Press release

Biosimilar Monoclonal Antibodies Market Size Expected to Reach USD 12960 Million by 2028: Valuates Reports

02-17-2022 08:19 AM CET | Health & Medicine

Press release from: Valuates Reports

Biosimilar Monoclonal Antibodies Market Size Expected to Reach

The global Biosimilar Monoclonal Antibodies market size is estimated to be worth US$ 5320.8 million in 2022 and is forecast to a readjusted size of US$ 12960 million by 2028 with a CAGR of 16.0% during the review period. Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Get Detailed Analysis of COVID-19 Impact on Biosimilar Monoclonal Antibodies Market @ https://reports.valuates.com/request/customisation/QYRE-Auto-34Z8707/Global_Biosimilar_Monoclonal_Antibodies_Market

Fully considering the economic change by this health crisis, Infliximab accounting for % of the Biosimilar Monoclonal Antibodies global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Oncology segment is altered to an % CAGR throughout this forecast period.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-34Z8707/global-biosimilar-monoclonal-antibodies

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type
➣Infliximab
➣Rituximab
➣Trastuzumab
➣Adalimumab
➣Other

Segment by Application
➣Oncology
➣Autoimmune Disease
➣Other

Consequence of Covid-19 Pandemic
The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Biosimilar Monoclonal Antibodies market back to the pre-covid levels.

Trends & Prospects
In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Regional and Country-level Analysis
➣North America
➣United States
➣Canada
➣Asia-Pacific
➣China
➣Japan
➣South Korea
➣India
➣Southeast Asia
➣Australia
➣Rest of Asia-Pacific
➣Europe
➣Germany
➣France
➣U.K.
➣Italy
➣Russia
➣Nordic Countries
➣Rest of Europe
➣Latin America
➣Mexico
➣Brazil
➣Rest of Latin America
➣Middle East & Africa
➣Turkey
➣Saudi Arabia
➣UAE
➣Rest of MEA

Key Market Players
➣Celltrion
➣Pfizer (Hospira)
➣3SBIO
➣Novartis (Sandoz)
➣Dr Reddy's
➣Celgen Biopharma
➣Cadila Healthcare
➣Hisun Pharma
➣Torrent Pharmaceuticals

Similar Reports:

Biopharmaceuticals Market: https://reports.valuates.com/market-reports/QYRE-Auto-22J2409/global-biopharmaceuticals

Medical Alert Systems Market: https://reports.valuates.com/reports/ALLI-Manu-2C82/medical-alert-systems

Medical Device Outsourcing Market: https://reports.valuates.com/reports/QYRE-Othe-1P494/medical-device-outsourcing

Valuates Reports
sales@valuates.com
For U.S. Toll Free Call +1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp : +91-9945648335

Website: https://reports.valuates.com
Twitter - https://twitter.com/valuatesreports
Linkedin - https://in.linkedin.com/company/valuatesreports
Facebook - https://www.facebook.com/valuatesreports/

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Monoclonal Antibodies Market Size Expected to Reach USD 12960 Million by 2028: Valuates Reports here

News-ID: 2555321 • Views:

More Releases from Valuates Reports

Selective Catalytic Reduction (SCR) System Market: Size, Share, Growth, Analysis …
Global Selective Catalytic Reduction (SCR) System Market The global Selective Catalytic Reduction (SCR) System market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. View sample report https://reports.valuates.com/request/sample/QYRE-Auto-8E7055/Global_Selective_Catalytic_Reduction_SCR_System_Market_Insights_and_Forecast_to_2028 North American market for Selective Catalytic Reduction (SCR) System is estimated to increase from $
Electric Vehicle Solid State Battery Market: Increase in demand for fast chargin …
The global electric vehicle solid state battery market is expected to be valued at $0.37 billion in 2025, and is projected to reach $1.9 billion by 2035, growing at a CAGR of 18% from 2025 to 2035. Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-4P945/Electric_Vehicle_Solid_State_Battery_Market_By_Vehicle_Type_Passenger_Car_Commercial_Vehicle_By_Propulsion_Type_Battery_Electric_Vehicle_Hybrid_Electric_Vehicle_By_Battery_Energy_Density_Less_than_450_Wh_kg_More_than_450_Wh_kg_Global_Opportunity_Analysis_and_Industry_Forecast_2025_2035 Factors, such as rising global pollution levels and depleting fossil fuels, have created demand for development of sustainable transportation systems. The automotive manufacturers have implemented innovative technologies to tackle the growing
Synthetic Fuel Market Research Report: North America dominated the synthetic fue …
The global synthetic fuel market was valued at $3.9 billion in 2021 and is projected to reach $22.5 billion by 2031, growing at a CAGR of 19.7% from 2022 to 2031. Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-1O754/Synthetic_Fuel_Market In recent years, many corporations and industry players are entering into collaborations or joint ventures for researching the possibilities of synthetic fuels. They are even collaborating with automobile and aviation giants to promote synthetic fuel. Aston Martin,
USB Retimer Market By Type (USB 3.0, USB 3.1, USB 3.2, USB 4, Others), By Applic …
USB Retimer Market According to a new report published by , titled, "USB Retimer Market," The usb retimer market was valued at $270.96 million in 2021, and is estimated to reach $1.4 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031. Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-0L907/USB_Retimer_Market_By_Type_USB_3_0_USB_3_1_USB_3_2_USB_4_Others_By_Application_Servers_Storage_Applications_Others_Global_Opportunity_Analysis_and_Industry_Forecast_2021_2031 The USB retimer market is segmented into type, application and region. On the basis of type, the market is divided into USB 3.0, USB

All 5 Releases


More Releases for Monoclonal

Impact COVID-19 on Monoclonal Antibodies Market 2021 Generated Opportunities for …
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017,
Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into
Global Monoclonal Antibody Diagnostic Reagents Market
Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Therefore, due to its importance in the clinical application, it
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity